* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
As a professional biomedical company, Creative Peptides focuses on providing a comprehensive and sophisticated peptide screening service system for scientific research partners. We rely on cutting-edge technology platform and rigorous quality management system to ensure that each functional peptide and therapeutic peptide screening work can be efficient and accurate, to provide strong support for your new drug research and development, biomarker exploration and other scientific research journey, accelerate the transformation process of scientific discovery to clinical application.
Given the great potential of peptides that penetrate the blood-brain barrier (BBB) in the treatment of neurodegenerative diseases, a highly simulated in vitro BBB model and the transwell experimental system, combined with advanced computational modeling techniques, were used to accurately evaluate the ability of each candidate peptide to cross the BBB. This screening strategy focuses on identifying peptides that efficiently deliver therapeutic drugs to the central nervous system, opening up new therapeutic avenues for neuroscientific treatment options.
The screening of organ-targeting peptides plays a key role in precision medicine, by precisely targeting specific organs or tissues, effectively improving treatment outcomes while reducing systemic side effects. We provide customized services covering multiple organs such as the heart, liver, spleen, lungs and kidneys to meet different research and treatment needs.
To identify peptides that can precisely target heart tissue or specific heart cell receptors to improve the treatment of diseases such as heart failure, myocardial infarction and arrhythmia. Through a refined screening and identification process, we aim to identify and optimize peptides that enhance the efficiency of cardiac drug delivery.
Screening for peptides that can specifically recognize liver cells or bind to liver-specific receptors such as ASGPR has important implications for the treatment of diseases such as hepatitis, cirrhosis and liver cancer. Through precise screening, these peptides can significantly enhance the accumulation of therapeutic agents in the liver and improve treatment efficiency.
To address the challenges of immune-related and respiratory diseases, we offer targeted peptide screening services for the spleen and lungs. By identifying peptides that specifically bind to spleen immune cells or lung tissue, we aim to optimize the targeted delivery of immunomodulatory drugs and drugs for the treatment of respiratory diseases, promoting therapeutic efficacy while reducing side effects.
Our screening platform is dedicated to the discovery of peptides that can efficiently target kidney cells or kidney tissospecific receptors, aiming to provide more precise delivery strategies for the treatment of acute kidney injury, chronic kidney disease and kidney cancer, with a view to enhancing the accumulation of drugs in the kidney and improving the therapeutic effect.
In the field of anticancer peptides, we focus on designing and screening antitumor peptides (ATPs) that can accurately target and eliminate cancer cells without harming healthy tissues. These peptides show remarkable therapeutic potential by inducing apoptosis of cancer cells, inhibiting neovascularization, and regulating immune responses against tumor cells. We not only construct complex tumor cell models and drug-resistant cell line libraries to select peptides with superior anti-tumor activity, but also use in-depth epigenetic and proteomic analysis to fully understand the mechanism of action of these peptides, paving the way for targeted treatment strategies for cancer.
Disease-specific peptide molecules, known as mimotopes, provide innovative insights into how diseases occur by mimicking key epitopes. Even with limited sequence similarity, these peptides can stimulate antibody responses similar to natural epitopes, opening up new avenues for the development of diagnostic reagents and preventive measures. Using phage display technology, peptides associated with specific diseases were screened from large-scale peptide libraries, such as the highly specific peptides in the sera of HPV, SARS and AIV patients. These Mimotope-based methods have significantly improved serological detection against H5N1 avian influenza virus, SARS, and rheumatoid arthritis. At the same time, by identifying peptides mimicking fetuin-A, they have revealed unknown initiation events in the development of prostate cancer, providing valuable clues to the study of disease mechanisms.
Antimicrobial peptides (AMPs), as the key components of natural immune defense, are widely effective against bacteria, fungi and viruses with their unique cationic properties. Our screening services incorporate high-throughput technologies, such as microfluidic and automated liquid handling, to comprehensively evaluate libraries of natural and synthetic sources of AMPs and precisely determine their minimum inhibitory concentrations (mics) against multiple microbial strains, accelerating the discovery of highly effective antimicrobial peptides.
Antiviral peptides (AVPs) have demonstrated a powerful ability to inhibit viral replication and transmission by intervening in key parts of the viral life cycle. Functional screening of large peptide libraries was used to identify peptides with significant inhibitory effects on influenza, HIV, hepatitis, coronavirus and other viruses. Combined with in vitro infection model, cytotoxicity analysis and viral replication dynamics study, the screened peptides not only have significant inhibitory effect, but also have high safety.
Immunomodulatory peptides (IMPs) show great potential in regulating the immune system response, treating autoimmune diseases, chronic inflammation and immunodeficiency diseases. By using advanced in vivo and in vitro immune experiments, peptides that can effectively regulate the function of immune cells and cytokine expression can be verified and selected from the rich peptide library to provide a solid foundation for the development of new immunotherapies. Creative Peptides ensured efficient recognition and characterization of disease-specific peptides through a customized biological screening process including serum preconditioning, multiple rounds of biological screening, and enrichment and identification of immunopositive phage clones.
1. What is peptide screening, and how does it work?
Peptide screening involves the identification and selection of peptides with specific properties or functions from large libraries of peptide sequences. It typically utilizes techniques such as phage display, yeast display, or cell surface display to present peptide libraries for screening against target molecules or biological systems. The screening process involves iterative rounds of selection and enrichment to isolate peptides with desired characteristics.
2. What are the potential applications of peptide screening?
Peptide screening has diverse applications in various fields, including drug discovery, diagnostics, vaccine development, and targeted therapy. It can be used to identify peptide ligands for specific receptors, enzyme inhibitors, vaccine antigens, diagnostic biomarkers, and therapeutic agents for various diseases.
3. How long does the peptide screening process typically take?
The duration of the peptide screening process can vary depending on factors such as the complexity of the screening target, the size of the peptide library, and the screening techniques employed. Generally, the process can take several weeks to months, including the time required for library construction, screening rounds, and subsequent characterization of selected peptides.
4. What is the difference between natural and synthetic peptide libraries?
Natural peptide libraries consist of peptide sequences derived from naturally occurring proteins or peptides, while synthetic peptide libraries are chemically synthesized and can encompass a broader range of peptide sequences. Natural libraries may offer greater diversity but are limited by the inherent variability of natural sequences, whereas synthetic libraries allow for precise control over peptide composition and properties.
5. How do you ensure the specificity and efficacy of screened peptides?
Peptide screening protocols are designed to include stringent selection criteria to ensure the specificity and efficacy of screened peptides. This may involve multiple rounds of selection, specificity testing against related targets, and functional assays to validate peptide activity. Additionally, bioinformatics tools and structural analyses may be employed to predict peptide-target interactions and optimize peptide designs.
6. What types of screening techniques do you use, and how do you select the most suitable approach for a given project?
We utilize a range of screening techniques, including phage display, yeast display, bacterial display, and cell surface display, depending on the nature of the target and the desired properties of screened peptides. The selection of the most suitable approach for a given project is based on factors such as target accessibility, peptide library size, and downstream applications.
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
GLP-1 is a 30 amino acid peptide (molecular weight of 3297.5) secreted by intestinal L-cells in response to meal ingestion wi ...
Studies on the binding affinities of darifenacin hydrobromide and human muscarinic receptor subtypes show strong ...
Brief information of orexin peptide The past several years have provided important insights into the physiological significan ...
Figure 1. The structural formula of montirelinMontirelin, an analog of thyrotrophin-releasing hormone (TRH) is m ...
Pergolide mesylate salt , also known as 8-beta-((methylthio)methyl)-D-6-propylergoline methanesulfonate, is a ...